JP2024112834A5 - - Google Patents

Download PDF

Info

Publication number
JP2024112834A5
JP2024112834A5 JP2024075968A JP2024075968A JP2024112834A5 JP 2024112834 A5 JP2024112834 A5 JP 2024112834A5 JP 2024075968 A JP2024075968 A JP 2024075968A JP 2024075968 A JP2024075968 A JP 2024075968A JP 2024112834 A5 JP2024112834 A5 JP 2024112834A5
Authority
JP
Japan
Prior art keywords
antisense oligonucleotide
linkage
sarm1
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024075968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024112834A (ja
JP7796797B2 (ja
Filing date
Publication date
Priority claimed from JP2022530807A external-priority patent/JP7528212B2/ja
Application filed filed Critical
Publication of JP2024112834A publication Critical patent/JP2024112834A/ja
Publication of JP2024112834A5 publication Critical patent/JP2024112834A5/ja
Application granted granted Critical
Publication of JP7796797B2 publication Critical patent/JP7796797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024075968A 2019-11-26 2024-05-08 神経保護のための方法および組成物 Active JP7796797B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962940437P 2019-11-26 2019-11-26
US62/940,437 2019-11-26
JP2022530807A JP7528212B2 (ja) 2019-11-26 2020-11-25 神経保護のための方法および組成物
PCT/US2020/062289 WO2021108602A1 (en) 2019-11-26 2020-11-25 Methods and compositions for neuroprotection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022530807A Division JP7528212B2 (ja) 2019-11-26 2020-11-25 神経保護のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2024112834A JP2024112834A (ja) 2024-08-21
JP2024112834A5 true JP2024112834A5 (cg-RX-API-DMAC7.html) 2024-11-11
JP7796797B2 JP7796797B2 (ja) 2026-01-09

Family

ID=74046136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530807A Active JP7528212B2 (ja) 2019-11-26 2020-11-25 神経保護のための方法および組成物
JP2024075968A Active JP7796797B2 (ja) 2019-11-26 2024-05-08 神経保護のための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022530807A Active JP7528212B2 (ja) 2019-11-26 2020-11-25 神経保護のための方法および組成物

Country Status (11)

Country Link
US (1) US12595481B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065714A1 (cg-RX-API-DMAC7.html)
JP (2) JP7528212B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119366A (cg-RX-API-DMAC7.html)
CN (1) CN115176002A (cg-RX-API-DMAC7.html)
AU (1) AU2020391206A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009772A2 (cg-RX-API-DMAC7.html)
IL (1) IL293123A (cg-RX-API-DMAC7.html)
MX (1) MX2022006146A (cg-RX-API-DMAC7.html)
TW (1) TW202134436A (cg-RX-API-DMAC7.html)
WO (1) WO2021108602A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021108602A1 (en) * 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection
CR20240380A (es) * 2022-03-14 2024-10-03 Lilly Co Eli Agentes de interferencia de arn de sarm1
CN116059367B (zh) * 2022-07-15 2025-02-18 浙江乘时佳生物科技有限公司 一种治疗阿尔茨海默症的sarm1抑制剂
IL318437A (en) * 2022-07-21 2025-03-01 Amylyx Pharmaceuticals Inc Compositions containing oligonucleotides, and methods of using them
TW202547525A (zh) 2024-02-02 2025-12-16 美商美國禮來大藥廠 SARM1 RNAi藥劑
GB202408068D0 (en) 2024-06-06 2024-07-24 Univ London Treatment of cancer of the central nervous system
WO2025261431A1 (zh) * 2024-06-19 2025-12-26 上海拓界生物医药科技有限公司 靶向SARM1的RNAi剂及其医药用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096830A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of protein kinase D2 expression
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US7901882B2 (en) * 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
JP2013003911A (ja) * 2011-06-17 2013-01-07 Sony Corp 電子機器、電子機器の制御方法およびプログラム
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
WO2017164230A1 (ja) 2016-03-23 2017-09-28 国立大学法人 岡山大学 リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用
EP3481857B1 (en) 2016-07-06 2026-02-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
EP3515426A1 (en) 2016-09-24 2019-07-31 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
WO2018154413A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
US12576130B2 (en) * 2017-10-18 2026-03-17 Washington University Dominant negative SARM1 molecules comprising a substitution at position 189, 190, 193, 194, 570 and/or 685 of SARM1
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
WO2021108602A1 (en) 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection

Similar Documents

Publication Publication Date Title
US11920132B2 (en) Oligonucleotide therapy for Leber congenital amaurosis
US5194428A (en) Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US6372427B1 (en) Cooperative oligonucleotides
CN115697420A (zh) 一种治疗赫勒氏综合征的方法和药物
JPWO2022270585A5 (cg-RX-API-DMAC7.html)
CN115516092A (zh) 血管生成素样3(ANGPTL3)的siRNA及其用途
Gryaznov Oligonucleotide N3′→ P5′ phosphoramidates as potential therapeutic agents
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
KR20080031164A (ko) SR 단백질의 결합의 방해에 의해 그리고 이차 RNA구조의 방해에 의한 pre-mRNA에서 엑손 인식의조절
JPH08510900A (ja) 改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド
JP2022520986A5 (cg-RX-API-DMAC7.html)
US5637573A (en) Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
JP2022536945A5 (cg-RX-API-DMAC7.html)
JP2024073525A5 (cg-RX-API-DMAC7.html)
JP2024506709A5 (cg-RX-API-DMAC7.html)
US5679555A (en) Method of using ribozyme analogs having rigid, non-nucleotidic molecular linkers
JP2023542889A5 (cg-RX-API-DMAC7.html)
CN115702006A (zh) 缀合基团及其缀合物
JP2024536132A5 (cg-RX-API-DMAC7.html)
WO2017186815A1 (en) Antisense oligonucleotides for enhanced expression of frataxin
JP2021513851A5 (cg-RX-API-DMAC7.html)
RU2024106447A (ru) Антисмысловые олигонуклеотиды, нацеленные на ген cav3.1, и их применения
AU2003236659B2 (en) Cooperative oligonucleotides
JP2024518788A5 (cg-RX-API-DMAC7.html)
JP2025522625A5 (cg-RX-API-DMAC7.html)